Oct 7, 2013
Kevin Kotler & Broadfin Capital Take a 5.2% Stake in Biodel
Biodel, Broadfin Capital : In a 13G filing reported a few minutes ago, Kevin Kotler 's Broadfin Capital disclosed ownership of a 5.2% stake in Biodel Inc , a company engaged in the development of diabetes treatments.
Biodel Target of Unusually High Options Trading
Biodel saw some unusual options trading on Monday. Stock investors acquired 5,676 put options on the stock, Stock Ratings Network reports.
Biodel's CEO Presents at Study 3-201Top Line Data Conference Call
Ladies and gentlemen, thank you for standing by. Welcome to Biodel Study 3-201 Top Line Data Conference Call.
Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial ...
Biodel Inc. today announced preliminary results from Study 3-201, a Phase 2 clinical study of BIOD-123, an investigational ultra-rapid-acting mealtime insulin, in patients with type 1 diabetes.